Cumberland Pharmaceuticals Inc. (CPIX)
Chart Events
Performance Outlook
| Previous Close | 2.1100 |
| Open | 2.0900 |
| Bid | 2.1200 x 1400 |
| Ask | 2.1500 x 800 |
| Day's Range | 2.0700 - 2.1500 |
| 52 Week Range | 2.0700 - 7.5100 |
| Volume | |
| Avg. Volume | 38,671 |
| Market Cap | 32.952M |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3410 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CPIX
Related Research
- Cumberland Pharmaceuticals Inc.PCRX: Raising target price to $68.00PACIRA BIOSCIENCES INC has an Investment Rating of BUY; a target price of $68.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.RatingFair ValueEconomic Moat9 days agoArgus Research
- Simply Wall St.
Estimating The Intrinsic Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Does the May share price for Cumberland Pharmaceuticals Inc. ( NASDAQ:CPIX ) reflect what it's really worth? Today, we...
- PR Newswire
Cumberland Pharmaceuticals Reports 6% Revenue Growth
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $11.2 million during the first quarter of 2022, - which is a 6% increase over the prior year period. Adjusted earnings for the quarter were $0.5 million, or $0.03 a share. The company ended the first quarter with $96.7 million in total assets, $55.9 million in total liabilities, and $41.0 million of sharehold
- PR Newswire
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to support Cumberland's new Sancuso® oncology support product.
